ArticleCureus2025
Reversible Subacute Parkinsonism and Cognitive Decline in a Patient With Acquired Hepatocerebral Degeneration: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hepatocerebral degeneration (AHD) is a rare neurological disorder associated with chronic liver disease and portosystemic shunting. It is characterized by parkinsonism, cognitive impairment, and bilateral hyperintensities in the globus pallidus on T1-weighted imaging. Although traditionally considered irreversible, recent reports suggest that AHD may be partially reversible with early intervention. We describe the case of a 71-year-old Japanese man with a history of chronic alcohol use and liver dysfunction who developed subacute parkinsonism and cognitive decline, initially preceded by depressive symptoms. He was treated for major depressive disorder before neurological signs emerged. Laboratory testing revealed macrocytic anemia, mild hepatic dysfunction, and hyperammonemia. T1-weighted imaging showed bilateral hyperintensities in the globus pallidus, despite a normal serum manganese level. A diagnosis of AHD was made based on these findings. Conservative treatment with IV branched-chain amino acids and oral lactulose led to rapid and marked clinical improvement. This case highlights the potential reversibility of early-stage AHD and emphasizes the importance of recognizing psychiatric symptoms, such as depression, as possible early manifestations. Recent literature has documented similar cases of AHD initially misdiagnosed as primary psychiatric disorders, underscoring the need for careful diagnostic evaluation when basal ganglia abnormalities are detected on MRI. Early recognition and metabolic correction may help prevent irreversible neurological damage and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.